Released Nov 3, 2022, before the open
10-Q filed Nov 3, 2022, 34 days after period end · 0000950170-22-021538
Q3 2022 · 10-Q
Revenue$114.00M$114.00M +1.4% vs Q3 2021−3.5% vs Q2 2022
Net Income-$10.72M-$10.72M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.53-$0.53 N/M vs Q3 2021N/M vs Q2 2022
Gross Profit$83,423,000−0.8%
Operating Income-$5,787,000N/M
Operating Cash Flowderived-$1,264,000N/M
Free Cash Flowderived-$6,391,000N/M
Margins · derived
Gross margin73.2%−1.6 pt vs Q3 2021
Operating margin-5.1%−4.8 pt vs Q3 2021
Net margin-9.4%−7.5 pt vs Q3 2021
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $114.00M | $112.43M | $110.99M | $113.50M |
| Net Income | -$10.72M | -$2.17M | $4.65M | -$40.50M |
| EPS Diluted | -$0.53 | $0.11 | $0.24 | -$2.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR